Today: 19 May 2026
Browse Category

LSE:NG.L 18 November 2025 - 4 March 2026

National Grid share price holds near 52-week high into weekend as BoE rate call looms

National Grid share price holds near 52-week high into weekend as BoE rate call looms

National Grid shares closed Friday at 1,234.5p, up 0.37%, after touching 1,240p. A U.S. SEC filing detailed updated voting rights and director share dealings. Traders are watching next week’s Bank of England rate decision, with utilities sensitive to shifts in gilt yields. About 10.2 million National Grid shares traded as the FTSE 100 marked its longest monthly winning streak in over 12 years.
31 January 2026
··
National Grid share price slips as gilt yields climb — what to watch next for NG.L

National Grid share price slips as gilt yields climb — what to watch next for NG.L

National Grid shares fell 0.65% to 1,222.5 pence in early London trading Thursday, retreating from a 52-week high set Wednesday. Rising UK gilt yields pressured utility stocks, as 10-year yields hit 4.569%, their highest since November. Investors await National Grid’s RIIO-T3 regulatory briefing on Thursday. Societe Generale may conduct price-support operations for a €500 million securities offering.
29 January 2026
·
National Grid plc Stock (NG.L / NGG): Latest News, Analyst Forecasts, Dividend Outlook and Key Catalysts on 16 December 2025

National Grid plc Stock (NG.L / NGG): Latest News, Analyst Forecasts, Dividend Outlook and Key Catalysts on 16 December 2025

Ofgem approved a £28bn UK grid upgrade plan, raising National Grid’s allowed investment and warning of a £108 rise in consumer bills by 2031. National Grid shares closed at 1,128p in London with a £55.9bn market cap. Ofgem’s RIIO-T3 Final Determination set a 6.12% real allowed cost of equity for National Grid Electricity Transmission from April 2026.
16 December 2025
···
National Grid (NG.L) Today—18 November 2025: New CEO Zoë Yujnovich takes charge, ex‑dividend this week, AI power plans sharpen focus on grid capacity

National Grid (NG.L) Today—18 November 2025: New CEO Zoë Yujnovich takes charge, ex‑dividend this week, AI power plans sharpen focus on grid capacity

Zoë Yujnovich took over as National Grid CEO on 17 November, succeeding John Pettigrew. The company’s ex-dividend date falls on 20 November, with the record date on 21 November. Ofgem confirmed tighter carbon-capture licence rules from 18 November, while government plans signal discounted power for AI data centres and faster grid connections. National Grid began upgrades at Didcot substation to support data centre and battery storage demand.
18 November 2025
·

Stock Market Today

  • GF Securities Raises Nvidia Price Target to $308 Ahead of Earnings
    May 19, 2026, 10:00 AM EDT. GF Securities raised its price target on Nvidia to $308 from $292 ahead of the chipmaker's fiscal first-quarter earnings, citing Nvidia's strong cash position and potential share buybacks. Analyst Jeff Pu noted a slight shift in the Rubin platform timeline but maintained the 2300W spec. The firm expects Nvidia to grow its data-center silicon market share with products like Vera CPU and LPX, and possibly launch an inferencing-focused GPU. While fiscal 2027 earnings estimates remain steady, fiscal 2028 forecasts rose by 13% due to anticipated higher Blackwell shipments and pricing, partially offset by lower Rubin unit assumptions.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

19 May 2026
Sunshine Biopharma shares surged as much as 516% before settling up 78% at $0.51 in heavy after-hours Nasdaq trading Monday, following a $6 million public offering priced at $0.50 per unit. More than 436 million shares changed hands, far exceeding the company’s 5 million shares outstanding. The deal includes 12 million units with warrants, raising dilution concerns. Closing is expected around May 19.
Go toTop